Clinical Trials Logo

Clinical Trial Summary

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common post-operative complication. The effectiveness of fondaparinux compared with other injectable anticoagulants in VTE following major orthopedic and abdominal surgery has been evaluated in database studies; however, the effectiveness of injectable anticoagulant medications following cancer-related surgeries in the practice setting has not been as well documented.

The objective of this study is to analyze patient records from a national hospital database and compare the outcomes and costs between four types of injectable anticoagulant medications that were prescribed for the prevention of VTE following cancer-related surgery. This analysis will assess and quantify the outcomes, resource utilization, and cost of care for patients receiving fondaparinux, enoxaparin, dalteparin or unfractionated heparin. The outcomes of interest include the occurence of VTE, rates of major bleeds, medical resource utilization, and total costs (medical plus pharmacy).

The source of data for this study is the Premier Perspective Databaseā„¢. This hospital claims database links de-identified inpatient medical, pharmacy, and billing data from more than 500 hospitals.

This study is a retrospective cohort study that uses propensity score matching to adjust for the differences between the numbers of patients treated with each medication.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01444612
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date February 2010
Completion date November 2010

See also
  Status Clinical Trial Phase
Completed NCT04503135 - Catheter Associated Asymptomatic Thrombosis in Intensive Care Unit
Completed NCT01691495 - ARIXTRA® Adherence in SVT Patients. N/A
Not yet recruiting NCT06149533 - Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients Phase 3
Active, not recruiting NCT05396157 - Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
Completed NCT00312013 - Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer Phase 3
Not yet recruiting NCT06288906 - Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems
Completed NCT00443053 - Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) Phase 3
Completed NCT00911157 - The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients Phase 3
Completed NCT00320398 - Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) Phase 3
Completed NCT01064362 - Hemorrhage Risk Prescribed Arixtra N/A
Recruiting NCT06440044 - Recurrence and Bleeding in Colorectal Cancer Patients With Cancer-associated Venous Thrombembolism
Recruiting NCT05710705 - Bioimpedance Measurement of Abdominal Free Flaps During Arterial and Venous Weaning in Breast Reconstruction N/A
Completed NCT00843492 - A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery Phase 3
Not yet recruiting NCT06349291 - Venous Thrombosis After Removal of Central Venous Catheter
Recruiting NCT06094387 - The Use of Thrombin Generation Assay in Detection of Central Line Related Thrombosis (CRT) in Critically Ill Patients